Skip to main content

Table 3 Biochemical analysis of 25-hydroxy vitamin D (25(OH) D), iPTH, calcium and phosphor of nursing mothers at baseline and week 12

From: The effect of vitamin D supplementation on body composition in nursing mothers with overweight or obesity: a randomized double-blind placebo-controlled clinical trial

Serum concentrations

Baseline

Week 12

Mean change (95% Confidence interval)

P-value b

VD1a

25.1 ± 11.2

20 ± 9.3

−5.1 (− 9.2/− 0.7)

0.001 [0.001]

25(OH)D (ng/ml)

VD2 a, c

PLa

16.5 ± 6.7

26.0 ± 7.6

28.8 ± 9.7

20.4 ± 6.8

12.3 (9.4/15.0)

− 5.6 (− 9.06/− 2.1)

 

Phosphor (mmol/I)

VD1

3.7 ± 0.5

3.6 ± 0.4

− 0.01 (− 0.2/0.2)

0.4 [0.4]

VD2

3.5 ± 0.8

3.7 ± 0.6

0.2 (− 0.1/0.5)

 

PL

3.5 ± 0.5

3.8 ± 0.6

0.25 (− 0.07/0.6)

 

Calcium (mmol/I)

VD1

8.6 ± 0.6

9.5 ± 0.4

0.9 (0.5/1.2)

0. 6 [0.6]

VD2

8.7 ± 0.6

9.3 ± 0.6

0.6 (0.2/1.0)

 

PL

8.3 ± 0.8

9.1 ± 0.5

0.8 (0.3/1.2)

 

Intact Parathyroid Hormone (pg/ml)

VD1

3 ± 1.1

4.6 ± 1

1.1 (0.4/1.8)

0.5 [0.4]

VD2

3.6 ± 1.6

4.7 ± 1.4

1.6 (1.0/2.2)

 

PL

3.1 ± 1.3

4.7 ± 1.6

1.6 (0.6/2.5)

 
  1. Data on baseline and week 12 are presented as mean ± standard deviation
  2. a three groups of 2000 IU vitamin D3/d (VD1), 4000 IU vitamin D3/d(VD2), and placebo (PL)
  3. b P-value is reported based on two-way repeated measure ANOVA (mixed ANOVA) to assess time effect and time by treatment effect interactions on all outcome variables after adjustment for saturated fatty acids intake before intervention. Numbers in brackets represent unadjusted P values
  4. c Significant difference with placebo and VD1 groups. (Obtained from two-way mixed ANOVA with Bonferroni correction)